Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation (Journal article)

Christodoulou, C./ Kostopoulos, I./ Kalofonos, H. P./ Lianos, E./ Bobos, M./ Briasoulis, E./ Gogas, H./ Razis, E./ Skarlos, D. V./ Fountzilas, G.

OBJECTIVE: Combination of trastuzumab and anthracyclines in metastatic breast cancer (MBC) is precluded due to cardiotoxicity. Pegylated liposomal doxorubicin (PLD) is the least cardiotoxic among the anthracyclines. We performed a phase II study of trastuzumab and PLD with biomarker evaluation. METHODS: Patients with MBC and HER2 overexpression, assessed as 3+ at local laboratories, received trastuzumab 8 mg/kg as loading dose followed by 6 mg/kg in combination with PLD 30 mg/m(2), both given every 3 weeks. To be eligible, patients should have received first-line chemotherapy for MBC or should have relapsed within a year of adjuvant taxane. Tumor tissue blocks were collected for central review and exploratory biomarker evaluation. Left-ventricular ejection fraction (LVEF) was closely monitored by cardiac ultrasound. RESULTS: Among 37 patients, an overall response rate of 22% was observed with a progression-free survival (PFS) of 6.5 months (0.8-31.1, 95% CI 2.7-10.3) and a survival of 18.7 months (1.6-40.8, 95% CI 3.7-33.7). No decline in LVEF was noticed. Overexpression of mTOR and TOP2A gene alterations were associated with better PFS. PTEN gene deletion was associated with resistance to treatment. CONCLUSION: Trastuzumab combined with PLD every 3 weeks is feasible, effective and safe in HER2-positive patients.
Institution and School/Department of submitter: Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής
Keywords: Adult,Aged,Antibodies, Monoclonal/*administration & dosage/adverse effects,Antibodies, Monoclonal, Humanized,Antineoplastic Combined Chemotherapy Protocols/*therapeutic use,Breast Neoplasms/chemistry/*drug therapy/mortality,Doxorubicin/administration & dosage/adverse effects/*analogs & derivatives,Humans,Middle Aged,PTEN Phosphohydrolase/analysis,Polyethylene Glycols/*administration & dosage/adverse effects,Protein Kinases/analysis,Receptor, erbB-2/analysis,TOR Serine-Threonine Kinases,Ventricular Function, Left/drug effects
URI: https://olympias.lib.uoi.gr/jspui/handle/123456789/20665
ISSN: 1423-0232
Link: http://www.ncbi.nlm.nih.gov/pubmed/19262067
http://content.karger.com/ProdukteDB/produkte.asp?doi=10.1159/000207504
Appears in Collections:Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά)

Files in This Item:
There are no files associated with this item.


 Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/20665
  This item is a favorite for 0 people.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.